Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1996-03-15
1997-11-25
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514 27, 514456, 514440, A61K 3119, A61K 31385
Patent
active
056913796
DESCRIPTION:
BRIEF SUMMARY
This application claims benefit of International application PCT/EP94/011110, filed Apr. 11, 1994.
BACKGROUND OF THE INVENTION
The present invention relates to the use of dihydrolipoic acid (6,8-dimercapto-octanic acid) in diseases of the eye and in intolerance reactions of the eye with implants, such as for example vitreous body and lens replacement material. Dihydrolipoic acid may also be used in the event of intolerance reactions of other body tissues with endoprostheses and implants.
Under physiological conditions, dihydrolipoic acid, the reduced form of .alpha.-lipoic acid, is involved in the regulation of the cellular redox state. Oxidation reactions due to certain highly reactive oxygen compounds have been found to trigger various symptoms through damage to cells and tissues.
Equilibria generally tend to exist intracellularly and extracellularly between the formation of reactive oxygen species and their requirement-oriented concentration regulation due to a balanced antioxidative system. This regulation system involves low molecular compounds such as vitamin A (retinol), vitamin C (ascorbic acid), vitamin E (.alpha.-tocopherol), uric acid and glutathion as well as special enzymes with antioxidative function. If this system is weakened or chronically overloaded, it should be augmented from outside by added antioxidants to achieve continuous protection against damage.
Blockage of the coenzyme .alpha.-lipoic acid is known to lead to impaired oxidative metabolism.
DE-A-40 35 456 discloses the use of dihydrolipoic acid for combating retroviruses, in particular the HIV virus. It is also possible to use a combination with another anti-retrovirally acting substance.
DE-A-40 02 706 describes dihydrolipoic acid as having an analgesic, anti-inflammatory and cytoprotective effect.
Furthermore, the radical-capturing and reducing effect of dihydrolipoic acid is known from the report published by universimed Verlag 1993 of a symposium (The status of antioxidants in the treatment of Diabetes mellitus). Kahler et al. report that dihydrolipoic acid displays a quench effect against peroxyl and superoxide radicals in cytosol and hydrophobic domains. Packer shows in connection with oxidative protective effect that a synergistic effect exists between vitamin E and/or vitamin C and dihydrolipoic acid. On the basis of model reactions, Burkart et al. raise the question as to whether dihydrolipoic acid should be used to suppress inflammatory processes in Type I diabetes. Elstner reports that the photooxidation of crystallines occurring due to radiation can be prevented by dihydrolipoic acid.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 shows the five main components of a lens homogenate obtained by means of FPLC filtration and the molecular weights allocated according to the retention time.
FIG. 2 shows results of an oxidation of SH-groups in a lens homogenate by exposed riboflavin and the influence of dihydrolipoic acid.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide pharmaceuticals which are suitable for the treatment or prophylaxis of diseases of the eye and for the suppression and prevention of intolerance reactions in the area between implants and living body tissue.
This object is solved by using dihydrolipoic acid or its physiologically acceptable salts to prepare pharmaceutical compositions for the treatment of disorders triggered by radicals in living body tissue.
The subordinate claims describe preferred embodiments of the use according to the invention.
DETAILED DESCRIPTION OF THE INVENTION
The disorders are in particular diseases of the eye, for example cataracts, retinopathy or retrolental fibroplasia and intolerance reactions in the area between implants and endoprostheses and living body tissue. Ophthalmological implants are particularly preferred. Treatment may already be prophylactic in order in particular to avoid or reduce intolerance reactions in the area between implants or endoprostheses and living body tissue.
Dihydrolipoic acid is able to exert a favourable influen
REFERENCES:
Seis, et al: "Antioxidant Functions of Vitamins", Ann. N.Y. Acad. Sci. vol. 669, 30 Sep. 1992, pp. 7-20, see p. 16, see p. 17-fig 6; see p. 18, line 4-7, line 15-20.
Kagan, et al: "Dihydrolipoic Acid--A Universal antioxidant both in the Membrane and in the Aqueous Phase", Biochem. Pharmacol. vol. 44, No. 8, 20 Oct. 1992, pp. 1637-1649, see abstract.
Prehn et al: "Dihydrolipoate Reduces Neuronal Injury After Cerebral Ischemia", J. Cereb.Blood Flow Metab., vol. 12, No. 1, Jan. 1992, pp. 78-87, see abstract.
Freialeben et al: "Free-radical Scavenging Activities, Interactions and Recycling of Antioxidants", Biochem. Soc. Trans., vol. 21, No. 2, May 1993, pp. 325-330, see p. 329.
Burkart, et al: "Dihydrolipoic acid Protects Pancreatic Islet Cells from Inflammatory Attach", Agents Actions, vol. 38, No. 1-2, Jan. 1993, pp. 60-65, see abstract.
Tsuchiya, et al: "Superoxide Formed from Cigarette Smoke Impairs Polymorphonuclear Leukocyte Active Oxygen Generation Activity", Arch.Biochem.Biophys. vol. 299, No. 1, Nov. 15, 1992, pp. 30-37, see abstract.
Suzuki, et al: "Antioxidant Activities of Dihydrolipoic acid and its Structural Homologues", Free Radiac Res. Commun., vol. 18, No. 2, 1993, pp. 115-122, see abstract.
Elstner Erich Franz
Ulrich Heinz
Asta Medica Aktiengesellschaft
Spivack Phyllis G.
LandOfFree
Dihydrolipoic acid as an ophthalmological agent to suppress into does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydrolipoic acid as an ophthalmological agent to suppress into, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydrolipoic acid as an ophthalmological agent to suppress into will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2107521